debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with ~$200M+ cash runway; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal sensitivity; no significant floating-rate debt; higher rates marginally reduce interest income on cash reserves
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API sourcing from China-based API manufacturers and specialized reagent suppliers in Europe are key chokepoints
Inferred
Agent_Inference
international_expansion_readiness
No international revenue; pre-commercial stage; sovereign currency devaluation exposure is effectively zero
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in US; no international revenue markets; currency devaluation risk is not applicable currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
CROs and CDMOs likely represent >30% of operational costs; switching mid-trial is highly disruptive and costly
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; cloud disruption would delay operations but not destroy core IP or trial data permanently
Inferred
Agent_Inference
business_model_type_secondary
R&D-driven drug development; secondary reliance on data management platforms and electronic data capture vendors
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling to EDC and clinical data platforms (e.g., Medidata/Veeva); switching mid-trial is operationally risky
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; equity shares represent ownership in a regulated public company, not an investment contract in a scheme
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; clinical trial data subject to FDA/ICH regulations; patient data handled via compliant CROs
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue, single-asset clinical stage company with no market power
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Zero current product revenue; 100% funded by equity raises; future revenue expected from drug royalties or licensing deals
Inferred
Agent_Inference
monetization_vector
Future monetization via drug sales, licensing, or partnership milestones; no transactional or subscription revenue today
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing likely based on oncology/diabetes specialty drug benchmarks ($50K–$200K+ annually)
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if BMF-219 achieves best-in-class outcomes; covalent MYC inhibition is a differentiated mechanism
Inferred
Agent_Inference
target_gross_margin_bracket
Branded specialty pharma gross margins typically 80–90%; achievable post-commercialization if manufacturing scales efficiently
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; drug IP is proprietary and protected; clinical trial participants are not customers in commercial sense
Inferred
Agent_Inference
headcount_cost_structure
R&D headcount-linear through clinical stages; commercialization would require significant headcount scaling for sales force
Inferred
Agent_Inference
marginal_cost_of_growth
Pre-commercial: growth requires proportional R&D and clinical spend; post-approval, marginal cost of revenue drops substantially
Inferred
Agent_Inference
franchise_compliance_risk
No franchise model; not applicable
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (post-launch), CAC driven by specialty sales force and oncologist/endocrinologist detailing; high upfront cost
Inferred
Agent_Inference
network_effect_present
No network effects present; drug efficacy is independent of user base size; value is purely clinical and scientific
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug discovery IP; AI tools may accelerate trial design and biomarker analysis
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; oncology drugs are non-discretionary; however, funding/capital raises are vulnerable in risk-off markets
Inferred
Agent_Inference
customer_segment_primary
Patients with hematologic malignancies (AML, ALL) and type 2 diabetes/obesity as primary target therapeutic areas
Inferred
Agent_Inference
customer_segment_secondary
Oncologists, endocrinologists, and hospital systems as prescribing/purchasing decision-makers post-commercialization
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to R&D and clinical trials; no legacy infrastructure drag; forward-looking burn of ~$80–100M/year
Inferred
Agent_Inference
sec_cik
0001840439
High
SEC-EDGAR
ticker
BMEA
High
SEC-EDGAR